Vitamin K2 (MK-7)observational2020

Modular Pathway Engineering of Bacillus subtilis To Promote De Novo Biosynthesis of Menaquinone-7.

ACS synthetic biology

confidence

Key findings

Modular pathway engineering of B. subtilis to boost MK-7 biosynthesis; final yield 69.5 mg/L after 144 h. No clinical/biological endpoints reported.

View source on PubMed (PMID 30543412) ↗

Sample size
N/A
Population
Bacillus subtilis 168 (engineered strain)
Dosing
N/A
Duration
144 h fermentation
Route
N/A
Blinding
not_reported
Controls
starting strain BS168NU
Drug class
fat-soluble vitamin
Full abstract

Menaquinone-7 (MK-7), a valuable vitamin K2, plays an important role in the prevention of osteoporosis and cardiovascular calcification. We chose B. subtilis 168 as the chassis for the modular metabolic engineering design to promote the biosynthesis of MK-7. The biosynthetic pathway of MK-7 was categorized into four modules, namely, the MK-7 pathway (Module I), the shikimate (SA) pathway (Module II), the methylerythritol phosphate (MEP) pathway (Module III), and the glycerol metabolism pathway (Module IV). Overexpression of menA (Module I) resulted in 6.6 ± 0.1 mg/L of MK-7 after 120 h fermentation, which was 2.1-fold that of the starting strain BS168NU (3.1 ± 0.2 mg/L). Overexpression of aroA, aroD, and aroE (Module II) had a negative effect on the synthesis of MK-7. Simultaneous overexpression of dxs, dxr, yacM, and yacN (Module III) enabled the yield of MK-7 to 12.0 ± 0.1 mg/L. Moreover, overexpression of glpD (Module IV) resulted in an increase of the yield of MK-7 to 13.7 ± 0.2 mg/L. Furthermore, deletion of dhbB reduced the consumption of the intermediate metabolite isochorismate, thus promoting the yield of MK-7 to 15.4 ± 0.6 mg/L. Taken together, the final resulting strain MK3-MEP123-Gly2-Δ dhbB with simultaneous overexpression of menA, dxs, dxr, yacM-yacN, glpD and deletion of dhbB enabled the yield of MK-7 to 69.5 ± 2.8 mg/L upon 144 h fermentation in a 2 L baffled flask.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.